initial public offerings (IPOs) trading on American exchanges

Monday, August 11, 2014

SAGE Therapeutics (SAGE) began trading on the NASDAQ on 18 July 2014


SAGE Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on development and commercialization of therapies for the treatment of life-threatening, rare central nervous system (CNS) disorders. The Company’s initial product candidates include SAGE-547, SAGE-689 and SAGE-217. The lead product candidate in its SE program, SAGE-547, is an intravenous (IV), agent in Phase 1/2 clinical development as an adjunctive therapy, a therapy combined with therapeutic approaches, for the treatment of super-refractory SE (SRSE). The Company’s follow-on product candidates, SAGE-689 and SAGE-217, utilize similar mechanistic pathways as SAGE-547 and are designed to have pharmaceutical properties which optimize both their non-clinical profiles and potential clinical profiles for the treatment of different stages of SE. SAGE-NCE is being developed as an intravenous therapy, as well as an oral stepdown therapy for status epilepticus and other seizure disorders.


215 1st St
CAMBRIDGE, MA 02142-1213
United States


Key stats and ratios

Q1 (Mar '14)2013
Net profit margin--
Operating margin--
EBITD margin--
Return on average assets-71.12%-317.19%
Return on average equity--

No comments:

Post a Comment